At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 100 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Real World Study: Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 Negative Breast Cancer Patients
In Brief
An observational study for Breast Cancer Metastatic and Treatment Outcome. Currently recruiting, targeting 100 participants across 1 site.
Detailed Summary
Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 negative Breast Cancer Patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Metastatic, Treatment Outcome
CountriesChina
Collaborators--
Timeline
N/ARecruiting
202520262027
Enrollment StartAug 2024
First PostedMay 2025
TodayJul 2026
Primary CompletionAug 2026
Study CompletionAug 2027
First PostedMay 11, 2025
Enrollment StartAug 12, 2024
Primary CompletionAug 1, 2026
Study CompletionAug 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 1.1 years agoPrimary completion in 1 month